Development and Evaluation of Virtual Reality Experiences for Cognitive Stimulation at the Sociosanitary Center El Carme (RTCSSC)

May 24, 2026 updated by: Jose Ferrer Costa, Badalona Serveis Assistencials

Desarrollo y evaluación de Experiencias en Realidad Virtual Para la estimulación Cognitiva en el Centro Sociosanitario El Carme de Badalona Servicios Asistenciales (BSA)

The goal of this clinical trial is to test a virtual reality (VR)-based program designed for cognitive stimulation in individuals attending the conventional cognitive rehabilitation program at the Day Hospital of CSSC (Centro Sociosanitario El Carme) in Badalona, Spain. The trial will specifically assess VR's impact on declarative memory and executive functions through interactive exercises, as well as attention and episodic memory through VR video stimuli.

The main questions it aims to answer are:

  • Will patients with mild cognitive impairment find the VR program enjoyable and easy to use?
  • Can VR interventions help improve patients' cognitive functions, specifically attention and memory?
  • Do healthcare professionals find VR a practical tool for cognitive stimulation in their clinical practice?

Participants will undergo a series of 8 sessions, scheduled twice a week to coincide with the conventional rehabilitation appointments. The VR equipment used will be Oculus Quest 2 headsets, offering an immersive experience with hand-tracking technology that simplifies interactions, particularly beneficial for those with mild cognitive impairment (MCI). During the study, participants will:

  • Engage with a VR-based cognitive stimulation program.
  • Undergo assessments of the participants´ cognitive functions before and after the intervention.
  • Provide feedback on the participants´ experience with the VR program.

Researchers will analyze the data to see if:

  • The VR program leads to noticeable improvements in the cognitive abilities of participants.
  • The program is well-received and deemed beneficial by both patients and healthcare professionals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background:

Cognitive impairment affects a significant portion of the aging population, leading to challenges in daily functioning and a reduced quality of life. Traditional cognitive rehabilitation techniques have shown benefits, but patient engagement and adherence remain challenging. Innovations such as virtual reality (VR) offer new avenues for cognitive stimulation, potentially enhancing patient involvement and treatment outcomes.

Study Design:

This clinical trial aims to evaluate the acceptability and efficacy of a VR-based cognitive stimulation program among patients with mild to moderate cognitive impairment at Centro Sociosanitario El Carme in Badalona. It will employ a pretest-posttest design to assess cognitive changes, utilizing standardized cognitive scales and gathering qualitative feedback on user experience.

Objectives:

Primary Objective: To assess the acceptability of the VR-based cognitive stimulation program among patients with mild to moderate cognitive impairment.

Secondary Objectives:

To evaluate whether the VR interventions are perceived as engaging and motivating by the patients, which would suggest positive adherence to the cognitive stimulation program.

To measure changes in cognitive performance, particularly in attention and memory, pre- and post-intervention, to determine the effectiveness of the program.

To understand healthcare professionals' perceptions of the applicability of VR interventions in clinical practice for cognitive stimulation.

To identify potential improvements for the implementation of the VR program based on patient and healthcare staff feedback.

To gather data that could be useful for the development of future VR experiences aimed at patients with cognitive impairments.

Methodology:

Participants will be recruited from the Centro Sociosanitario El Carme and will undergo an initial assessment to establish a cognitive baseline. The participants will then engage in a series of VR sessions designed to provide cognitive stimulation. The program will focus on exercises to enhance attention and memory, incorporating interactive elements to maintain engagement. After completing the sessions, participants will be re-assessed using the same cognitive scales.

Feedback on the VR experience will be collected through structured interviews and questionnaires to gauge acceptability, perceived usefulness, and motivation. Healthcare professionals involved in the administration of the VR program will also be interviewed to understand their views on the integration of VR into therapeutic practices.

Expected Outcomes:

It is hypothesized that the VR program will be well-received by patients, evidenced by high rates of program completion and positive subjective feedback. Post-intervention improvements in cognitive scale scores are expected, indicating the potential efficacy of VR-based stimulation. Insights from healthcare professionals are anticipated to highlight the practicality of VR in clinical settings and suggest improvements for future applications.

Relevance:

The findings from this trial could support the adoption of VR technologies in cognitive rehabilitation, offering a novel, scalable, and potentially more effective approach to managing cognitive impairments. The study may also contribute to the evidence base required for integrating technological innovations into standard healthcare practice.

Conclusion:

By exploring the intersection of VR technology and cognitive rehabilitation, this study seeks to advance the understanding of innovative treatments for cognitive impairments and foster improved patient outcomes through enhanced engagement and stimulation.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Barcelona
      • Badalona, Barcelona, Spain, 08917
        • Centro Socio Sanitario El Carmen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants must be classified as having mild cognitive impairment with a Mini-Mental State Examination (MMSE) score greater than 23.
  • Participants must be currently attending cognitive rehabilitation sessions at the Day Hospital of the Centro Sociosanitario El Carme (CSSC).
  • Participants must be able to give informed consent or, in the case of incapacity, consent must be obtained from their legal representative.

Exclusion Criteria:

  • Patients with a severe or unstable illness that could interfere with participation in the study.
  • Patients with serious psychiatric disorders, such as psychotic disorders, delusions, or hallucinations that may be exacerbated by the use of virtual reality.
  • Patients with severe visual limitations that would prevent the use of virtual reality.
  • Presence of ocular diseases causing blurred vision that cannot be corrected with contact lenses or glasses.
  • Presence of auditory pathologies that cause a significant decrease in hearing without hearing aids.
  • High sensitivity to motion sickness.
  • Subjects with epilepsy.
  • Patients who are unable or unwilling to give informed consent.

Withdrawal Criteria

The emergence of health problems that could interfere with the continuity of participation in the study, or the withdrawal of consent by the participant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual Reality Cognitive Stimulation Program

Participants with MCI undergo 8 VR sessions, using Oculus Quest 2 headsets for immersive cognitive exercises. Activities include a Supermarket Shopping Task for memory, a Payment Task for cognitive flexibility, and a Recipe Sequencing Task for problem-solving. Additionally, 360-degree videos with visuo-verbal stimulation are used to engage attention and episodic memory, monitored by therapists.

The investigators employ Oculus Quest 2 VR headsets with hand tracking technology to provide a seamless and immersive experience, especially beneficial for participants with Mild Cognitive Impairment (MCI).
Device: Virtual Reality Cognitive Stimulation Program
Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comfort of VR Headset as Measured by an 8-Item SUS:
Time Frame: immediately post-intervention, within 30 minutes after the 8th session (day 8)

Adapted 8-Item VR Headset Comfort Rating:

Score Range: 0 to 100 points Interpretation: Lower scores indicate better comfort (as most items measure discomfort).
immediately post-intervention, within 30 minutes after the 8th session (day 8)
Usability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS)
Time Frame: immediately post-intervention, within 30 minutes after the last intervention session- 8th session (day 8)

Adapted 8-Item System Usability Scale (SUS):

Score Range: 0 to 100 points Interpretation: Higher scores indicate better usability.
immediately post-intervention, within 30 minutes after the last intervention session- 8th session (day 8)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Professional´s Usability of VR Exercises as Measured by an Adapted 8-Item SUS:
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate a professional's perception of better system usability for patient care.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
VR Headset Comfort Rating for Professionals as Measured by an Adapted 3-Item SUS:
Time Frame: immediately post-intervention, within 30 minutes after the 8th session (day 8)
Scale Title: Professional System Usability Scale (SUS) Score Range: 0 to 100 points Interpretation: Higher scores indicate better comfort and ease of use for the VR headset; lower scores indicate greater discomfort and difficulty with use. This rating is based on a professional assessment of the VR headset's weight, design, and control scheme's impact on patient comfort during use.
immediately post-intervention, within 30 minutes after the 8th session (day 8)
Global Cognition as Measured by the Mini-Mental State Examination (MMSE)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
MMSE is a 30-point questionnaire evaluating orientation, attention, recall, language, and visual construction Score Range: 0 to 30 points. Higher scores means better global cognition function
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Global Cognition as Measured by the Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

MoCA is a 30-point screening tool for global cognitive function, assessing memory, attention, language, visuospatial skills, and executive function.

Score Range: 0 to 30 points

- Higher scores means better global cognition function
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Short-Term Memory as Measured by the Digit Span Test (DST Forward Span)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

Forward Digit Span measures verbal short-term memory. Score Range: 0 to 9 points

- Higher scores indicate better short-term verbal memory.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Working Memory as Measured by the Digit Span Test (DST Backward Span)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Backward Digit Span assesses working memory and mental manipulation. Score Range: 0 to 9 points. Higher scores indicate better working memory.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Visuospatial Attention as Measured by the Trail Making Test Part A (TMT-A)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

TMT-A measures visual attention and processing speed. The outcome is time to completion measured in seconds, typically ranging from several seconds to several minutes.

Lower times (faster completion) indicate better visuospatial attention.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Executive Function as Measured by the Trail Making Test Part B (TMT-B)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

TMTB: Trial Making Test B. Score Range: Time to complete the test measured in seconds, typically ranging from several seconds to several minutes.

Lower times (faster completion) indicate better alternating attention.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)
Processing Speed as Measured by the Symbol Digit Modalities Test (SDMT)
Time Frame: Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

SDMT: Symbol Digit Modalities Test. The Symbol Digit Modalities Test (SDMT) measures processing speed, attention, and visual-motor coordination. During the test, participants are required to match abstract symbols with corresponding numbers using a key. The total raw score is calculated as the number of correct symbol-digit pairs completed within a 90-second interval. There is no fixed maximum score, as it varies based on individual performance.

Higher scores indicate better processing speed and cognitive performance.
Baseline and immediately post-intervention, within 30 minutes after the 8th session (day 8)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demographics Variables
Time Frame: Baseline
Age: numeric
Baseline
Demographics Variables
Time Frame: Baseline
Gender: 0=female, 1=male, 3=others
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Badalona Serveis Assistencials

Collaborators

Public Health Agency of Barcelona
Reality Telling SL

Investigators

  • Principal Investigator: Jose Ferrer Costa, MD, Medical Researcher and Project Manager

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2023

Primary Completion (Actual)

February 27, 2024

Study Completion (Actual)

March 27, 2024

Study Registration Dates

First Submitted

November 3, 2023

First Submitted That Met QC Criteria

December 1, 2023

First Posted (Actual)

December 4, 2023

Study Record Updates

Last Update Posted (Actual)

June 11, 2026

Last Update Submitted That Met QC Criteria

May 24, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PI-23-195

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Not applicable; individual participant data will not be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe